Rectal Cancer, Version 6.2020 Featured Updates to the NCCN Guidelines
Rectal Cancer, Version 6.2020 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2020.0032
复制
发表时间：
2020-07-01
影响因子：
13.4
通讯作者：
Gurski, Lisa A.
中科院分区：
文献类型：
--
作者：
Benson, Al B., III;Venook, Alan P.;Gurski, Lisa A.
NCCN直肠癌指南为直肠癌患者的诊断、评估、治疗和随访提供了建议。这些NCCN指南见解总结了最近对指南进行重要更新的小组讨论。这些更新包括澄清直肠的定义并将直肠与乙状结肠区分开来;局部直肠癌的完全新辅助治疗方法;转移性结直肠癌的生物标志物靶向治疗，重点关注BRAF V600 E或HER 2扩增阳性疾病患者的新治疗选择。
The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E- or HER2 amplification- positive disease.